Studies related to CD4 Lymphocytes and Andrographis paniculata

A Phase I Trial Of Andrographolide In HIV Positive Patients And Normal Volunteers

Effect Decrease
Trial Design Non-controlled trial
Trial Length n/a
Number of Subjects 17
Sex n/a
Notes for this study:
Andrographolide at up to 30mg daily failed to influence the amount of the HIV virus in persons with HIV and increased serum liver enzymes, although it acted to normalize CD4+ T-cells (suppressed in persons with HIV). In a small cohort of persons without HIV, CD4+ T-cells were reduced.

Full details on all 2 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.